The Impact of Psilocybin on Pain in Fibromyalgia Patients (PsiloFM)

This within-subject, double-blind, randomized placebo-controlled study will test two low doses of oral psilocybin (5 mg and 10 mg) versus placebo in 35 fibromyalgia patients to assess effects on experimental pain sensitivity (Cold Pressor Test and Pressure Pain Threshold).

Participants attend five visits over five weeks including screening/familiarization, three dosing sessions (placebo, 5 mg, 10 mg, randomized order) with experimental tasks, blood sampling and questionnaires, and a final online follow-up; a brief hypnotic induction is applied before one CPT to test moderation of analgesic response.